ES2177787T3 - Uso de hidroxietil-almidon para evitar la formacion de adhesiones post-operatorias y como dispositivo de barrera intra-cavidades. - Google Patents

Uso de hidroxietil-almidon para evitar la formacion de adhesiones post-operatorias y como dispositivo de barrera intra-cavidades.

Info

Publication number
ES2177787T3
ES2177787T3 ES96916821T ES96916821T ES2177787T3 ES 2177787 T3 ES2177787 T3 ES 2177787T3 ES 96916821 T ES96916821 T ES 96916821T ES 96916821 T ES96916821 T ES 96916821T ES 2177787 T3 ES2177787 T3 ES 2177787T3
Authority
ES
Spain
Prior art keywords
hes
hydroxietil
almidon
adhesions
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916821T
Other languages
English (en)
Inventor
Gere Stodder Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23915271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177787(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2177787T3 publication Critical patent/ES2177787T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

SE DESCRIBE EL HIDROXIETILALMIDON (HES) Y EL USO DEL MISMO EN PROCEDIMIENTOS PARA REDUCIR O PREVENIR LA FORMACION DE UNA ADHESION ENTRE SUPERFICIES TISULARES, POR EJEMPLO SUPERFICIES DE ORGANOS, EN CAVIDADES CORPORALES DESPUES DE PROCEDIMIENTOS QUIRURGICOS Y PARA LA ADMINISTRACION DE FARMACOS. EL HES PUEDE UTILIZARSE COMO UNA BARRERA MECANICA ABSORBIBLE POR SI SOLO O JUNTO CON UNO O MAS COMPUESTOS ANTI RA LA APLICACION A AREAS DAÑADAS DE TEJIDOS, POR EJEMPLO ORGANOS, SITUADOS EN CAVIDADES CORPORALES TALES COMO LAS CAVIDADES PERITONEAL, PELVICA, PLEURAL, EL SISTEMA NERVIOSO CENTRAL Y EL ESPACIO INTERLIGAMENTOSO. EL HES TAMBIEN PUEDE UTILIZARSE COMO UN DISPOSITIVO VEHICULO INTRACAVIDAD PARA LA ADMINISTRACION DE AGENTES FARMACEUTICAMENTE ACTIVOS.
ES96916821T 1995-06-07 1996-05-31 Uso de hidroxietil-almidon para evitar la formacion de adhesiones post-operatorias y como dispositivo de barrera intra-cavidades. Expired - Lifetime ES2177787T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/482,235 US5807833A (en) 1995-06-07 1995-06-07 Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device

Publications (1)

Publication Number Publication Date
ES2177787T3 true ES2177787T3 (es) 2002-12-16

Family

ID=23915271

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916821T Expired - Lifetime ES2177787T3 (es) 1995-06-07 1996-05-31 Uso de hidroxietil-almidon para evitar la formacion de adhesiones post-operatorias y como dispositivo de barrera intra-cavidades.

Country Status (9)

Country Link
US (1) US5807833A (es)
EP (1) EP0831856B1 (es)
JP (2) JP4184431B2 (es)
AT (1) ATE221782T1 (es)
AU (1) AU722836B2 (es)
CA (1) CA2223573C (es)
DE (1) DE69622863T2 (es)
ES (1) ES2177787T3 (es)
WO (1) WO1996040168A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807833A (en) * 1995-06-07 1998-09-15 University Of Southern California Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
GB9810127D0 (en) 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
EP1085920B1 (en) * 1998-05-13 2001-12-19 ML Laboratories PLC Dextrin-containing composition for preventing surgical adhesions
AU2002233952A1 (en) * 2000-12-05 2002-06-18 Haemonetics Corporation Method for precipitating red blood cells
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
EP1809303B1 (en) * 2004-09-23 2019-03-06 ARC Medical Devices, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US9119901B2 (en) * 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US20090062233A1 (en) 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
CN104888263B (zh) 2008-01-14 2018-11-30 北京环球利康科技有限公司 生物相容性止血、防粘连、促愈合、外科封闭的变性淀粉材料
EP2832360A1 (en) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456346B (sv) * 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
JPS62228021A (ja) * 1986-02-24 1987-10-06 エチコン・インコ−ポレ−テツド 手術後の癒着の形成を防止または減少する方法
US4913903A (en) * 1987-02-04 1990-04-03 Alza Corporation Post-surgical applications for bioerodible polymers
US5080893A (en) * 1988-05-31 1992-01-14 University Of Florida Method for preventing surgical adhesions using a dilute solution of polymer
SE8900586L (sv) * 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
JP3174400B2 (ja) * 1992-05-28 2001-06-11 味の素ファルマ株式会社 腹腔洗浄液
DE4242926C2 (de) * 1992-12-18 1994-12-15 Fresenius Ag Dialyselösung für die Peritonealdialyse
US5807833A (en) * 1995-06-07 1998-09-15 University Of Southern California Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof

Also Published As

Publication number Publication date
EP0831856A2 (en) 1998-04-01
JPH11506741A (ja) 1999-06-15
EP0831856B1 (en) 2002-08-07
AU5956996A (en) 1996-12-30
JP2008264495A (ja) 2008-11-06
DE69622863T2 (de) 2002-12-12
DE69622863D1 (de) 2002-09-12
US5807833A (en) 1998-09-15
WO1996040168A2 (en) 1996-12-19
ATE221782T1 (de) 2002-08-15
WO1996040168A3 (en) 1997-01-23
JP4184431B2 (ja) 2008-11-19
CA2223573A1 (en) 1996-12-19
CA2223573C (en) 2011-09-20
AU722836B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
ES2177787T3 (es) Uso de hidroxietil-almidon para evitar la formacion de adhesiones post-operatorias y como dispositivo de barrera intra-cavidades.
BRPI0512604A (pt) terapia de drogas em combinação para reduzir a formação de tecido de cicatrização
CA2174072A1 (en) Hydrogel-forming, self-solvating absorbable polyester block copolymers, and methods for use thereof
EP0952171A3 (en) Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
NO20001567L (no) Bioadhesive sammensetninger og fremgangsmÕter for topisk administrering av aktive midler
WO1997005185A3 (en) Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
CA2235919A1 (en) Non-polymeric sustained release delivery system
SE8900586L (sv) Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
AU2742401A (en) Methods and compositions for improved delivery devices
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
BRPI0415649A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
EP2281828A3 (en) Compositions comprising modified erythropoietin
BR0012863A (pt) Composições farmacêuticas de "beta"-carbolina
BR9713480A (pt) Recipiente de plástico flexìvel com três câmaras.
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
EP0640647A3 (en) Ion-crosslinked glycosaminoglycan gels to increase soft tissue and for drug delivery.
BR0007360A (pt) Composição de liberação controlada
EP1057484A4 (en) INHIBITORS OF CELL DEATH
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ATE509637T1 (de) Temperaturgesteuerte verabreichungssysteme
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
WO1999013054A3 (en) Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
BRPI0413474A (pt) uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
EP1152002A4 (en) PYRROL DERIVATIVES AND CELL DEATH INHIBITORS